Sankyo is designing a new clinical trial for CS-917 for type 2 diabetes, with plans for a mid-stage study launch in the fourth quarter following discussions with the FDA. The announcement came from Sankyo's drug partner, Metabasis Therapeutics. Sankyo had halted research after seeing the level of lactic acid shoot up to dangerous levels in two patients involved in an earlier trial combining CS-917 and metformin. Researchers say that combination may be contraindicated but that a new trial could look at other combinations safely.
- read this article from the AP for more